{"title":"过氧化氧还蛋白1通过激活NLRP3/GSDMD通路,诱导结直肠癌细胞焦亡,从而抑制肿瘤发生。","authors":"Ying He, Jing Liu, Ning Zhou, Ling-Xiang Xie, Yong-Fang Jiang, Chun-Lan Chen","doi":"10.3748/wjg.v31.i36.111557","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Damage associated molecular patterns (DAMPs) are vital for the immunogenic cell death of cancer cells and can enhance the anti-tumor activity of immune cells in colorectal cancer (CRC). Peroxiredoxin 1 (Prdx1), an important DAMP, is highly expressed in various tumor tissues including CRC. However, the role of Prdx1 in CRC remains unknown.</p><p><strong>Aim: </strong>To investigate the effect and mechanisms of Prdx1 on CRC.</p><p><strong>Methods: </strong>Patients diagnosed with CRC in our medical center were included in this study to verify the expression of Prdx1 in cancer tissues. Recombinant Prdx1 (rPrdx1) was used to stimulate RKO and SW480 colon cancer cells. The cell survival rate, migration, proliferation and invasion ability were assessed. Transmission electron microscopy, TUNEL assay, lactate dehydrogenase release assay, and Western blot were used to determine the effect of Prdx1 on pyroptosis. NLRP3 inflammasome inhibitor and gasdermin D (GSDMD) inhibitor were used to explore the mechanism of Prdx1-induced pyroptosis.</p><p><strong>Results: </strong>The mRNA and protein levels of Prdx1 were significantly increased in the tumor tissues of patients with CRC. rPrdx1 inhibited the viability, proliferation, migration and invasion of RKO and SW480 colon cancer cells. Further study found that rPrdx1 inhibited the malignant biological behaviors of CRC cells by inducing pyroptosis rather than apoptosis and necroptosis. Mechanistically, rPrdx1 induces pyroptosis of CRC cells by activating the NLRP3 inflammasome/GSDMD pathway.</p><p><strong>Conclusion: </strong>Prdx1 induces pyroptosis by activating the NLRP3 inflammasome/GSDMD pathway, thereby inhibiting the malignant biological behavior of RKO and SW480 colon cancer cells.</p>","PeriodicalId":23778,"journal":{"name":"World Journal of Gastroenterology","volume":"31 36","pages":"111557"},"PeriodicalIF":5.4000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476671/pdf/","citationCount":"0","resultStr":"{\"title\":\"Peroxiredoxin 1 inhibits tumorigenesis by activating the NLRP3/GSDMD pathway to induce pyroptosis of colorectal cancer cells.\",\"authors\":\"Ying He, Jing Liu, Ning Zhou, Ling-Xiang Xie, Yong-Fang Jiang, Chun-Lan Chen\",\"doi\":\"10.3748/wjg.v31.i36.111557\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Damage associated molecular patterns (DAMPs) are vital for the immunogenic cell death of cancer cells and can enhance the anti-tumor activity of immune cells in colorectal cancer (CRC). Peroxiredoxin 1 (Prdx1), an important DAMP, is highly expressed in various tumor tissues including CRC. However, the role of Prdx1 in CRC remains unknown.</p><p><strong>Aim: </strong>To investigate the effect and mechanisms of Prdx1 on CRC.</p><p><strong>Methods: </strong>Patients diagnosed with CRC in our medical center were included in this study to verify the expression of Prdx1 in cancer tissues. Recombinant Prdx1 (rPrdx1) was used to stimulate RKO and SW480 colon cancer cells. The cell survival rate, migration, proliferation and invasion ability were assessed. Transmission electron microscopy, TUNEL assay, lactate dehydrogenase release assay, and Western blot were used to determine the effect of Prdx1 on pyroptosis. NLRP3 inflammasome inhibitor and gasdermin D (GSDMD) inhibitor were used to explore the mechanism of Prdx1-induced pyroptosis.</p><p><strong>Results: </strong>The mRNA and protein levels of Prdx1 were significantly increased in the tumor tissues of patients with CRC. rPrdx1 inhibited the viability, proliferation, migration and invasion of RKO and SW480 colon cancer cells. Further study found that rPrdx1 inhibited the malignant biological behaviors of CRC cells by inducing pyroptosis rather than apoptosis and necroptosis. Mechanistically, rPrdx1 induces pyroptosis of CRC cells by activating the NLRP3 inflammasome/GSDMD pathway.</p><p><strong>Conclusion: </strong>Prdx1 induces pyroptosis by activating the NLRP3 inflammasome/GSDMD pathway, thereby inhibiting the malignant biological behavior of RKO and SW480 colon cancer cells.</p>\",\"PeriodicalId\":23778,\"journal\":{\"name\":\"World Journal of Gastroenterology\",\"volume\":\"31 36\",\"pages\":\"111557\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476671/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3748/wjg.v31.i36.111557\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3748/wjg.v31.i36.111557","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:损伤相关分子模式(DAMPs)对肿瘤细胞的免疫原性死亡至关重要,并能增强结直肠癌(CRC)免疫细胞的抗肿瘤活性。过氧化氧还蛋白1 (Prdx1)是一种重要的DAMP,在包括CRC在内的多种肿瘤组织中高表达。然而,Prdx1在CRC中的作用尚不清楚。目的:探讨Prdx1在结直肠癌中的作用及其机制。方法:本研究纳入我院诊断为结直肠癌的患者,验证Prdx1在癌组织中的表达。利用重组Prdx1 (rPrdx1)刺激RKO和SW480结肠癌细胞。测定细胞存活率、迁移能力、增殖能力和侵袭能力。采用透射电镜、TUNEL法、乳酸脱氢酶释放法、Western blot法检测Prdx1对焦亡的影响。采用NLRP3炎性小体抑制剂和gasdermin D (GSDMD)抑制剂探讨prdx1诱导的焦亡机制。结果:结直肠癌患者肿瘤组织中Prdx1 mRNA和蛋白水平显著升高。rPrdx1抑制RKO和SW480结肠癌细胞的生存、增殖、迁移和侵袭。进一步研究发现,rPrdx1通过诱导CRC细胞焦亡而非凋亡和坏死亡来抑制CRC细胞的恶性生物学行为。机制上,rPrdx1通过激活NLRP3炎性体/GSDMD通路诱导结直肠癌细胞焦亡。结论:Prdx1通过激活NLRP3炎性体/GSDMD通路诱导焦亡,从而抑制RKO和SW480结肠癌细胞的恶性生物学行为。
Peroxiredoxin 1 inhibits tumorigenesis by activating the NLRP3/GSDMD pathway to induce pyroptosis of colorectal cancer cells.
Background: Damage associated molecular patterns (DAMPs) are vital for the immunogenic cell death of cancer cells and can enhance the anti-tumor activity of immune cells in colorectal cancer (CRC). Peroxiredoxin 1 (Prdx1), an important DAMP, is highly expressed in various tumor tissues including CRC. However, the role of Prdx1 in CRC remains unknown.
Aim: To investigate the effect and mechanisms of Prdx1 on CRC.
Methods: Patients diagnosed with CRC in our medical center were included in this study to verify the expression of Prdx1 in cancer tissues. Recombinant Prdx1 (rPrdx1) was used to stimulate RKO and SW480 colon cancer cells. The cell survival rate, migration, proliferation and invasion ability were assessed. Transmission electron microscopy, TUNEL assay, lactate dehydrogenase release assay, and Western blot were used to determine the effect of Prdx1 on pyroptosis. NLRP3 inflammasome inhibitor and gasdermin D (GSDMD) inhibitor were used to explore the mechanism of Prdx1-induced pyroptosis.
Results: The mRNA and protein levels of Prdx1 were significantly increased in the tumor tissues of patients with CRC. rPrdx1 inhibited the viability, proliferation, migration and invasion of RKO and SW480 colon cancer cells. Further study found that rPrdx1 inhibited the malignant biological behaviors of CRC cells by inducing pyroptosis rather than apoptosis and necroptosis. Mechanistically, rPrdx1 induces pyroptosis of CRC cells by activating the NLRP3 inflammasome/GSDMD pathway.
Conclusion: Prdx1 induces pyroptosis by activating the NLRP3 inflammasome/GSDMD pathway, thereby inhibiting the malignant biological behavior of RKO and SW480 colon cancer cells.
期刊介绍:
The primary aims of the WJG are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in gastroenterology and hepatology.